Skip to main content

Table 4 Multivariate competing risks regression analysis for risk of CRC death, all CRC patients

From: Sociodemographic disparities in survival from colorectal cancer in South Australia: a population-wide data linkage study

  

CRC death/ no. at risk

All CRC (n = 4365)

HR

95 % CI

p-value

Site

Colon

923/2847

1.00

-

-

Rectum

487/1518

0.85

0.74-0.98

0.022

Stage dukes

A

55/933

1.00

-

-

B

250/1438

2.97

2.21-3.99

0.000

C

520/1345

7.74

5.75-10.4

0.000

D

585/649

34.1

25.0-46.5

0.000

Grade

Low

10/114

1.00

-

-

Intermediate

826/3137

1.22

0.72-2.07

0.453

High

405/825

2.25

1.32-3.84

0.003

Unknown

159/289

2.09

1.20-3.64

0.010

Age group

50-59

298/901

1.00

-

-

60-69

467/1552

1.04

0.89-1.21

0.600

70-79

645/1942

1.12

0.96-1.29

0.146

Sex

Female

585/1867

1.00

-

-

Male

825/2498

1.07

0.95-1.20

0.243

Private Insurance

No

686/1985

1.00

-

-

Yes

724/2380

0.95

0.84-1.06

0.335

Comorbidity

None

941/3068

1.00

-

-

One (not severe)

248/779

0.90

0.78-1.05

0.194

Multiple / severe

221/518

1.21

1.02-1.44

0.033

SES quintile

Low

382/1072

1.00

-

-

Low-mid

280/878

0.94

0.80-1.11

0.443

Middle

246/791

0.93

0.78-1.10

0.379

Mid-high

276/843

1.06

0.90-1.25

0.508

High

226/781

0.75

0.62-0.91

0.004

Residence

Urban

1007/3102

1.00

-

-

Outer urban

122/429

0.95

0.79-1.16

0.638

Rural

47/188

0.98

0.82-1.17

0.830

Remote

93/242

1.12

0.90-1.39

0.324

Surgerya

No

230/295

1.00

-

-

Yes

1180/4070

0.51

0.42-0.62

0.000

Radiotherapya

No

1141/3757

1.00

-

-

Yes

36/269

1.41

1.18-1.68

0.000

Chemotherapya

No

632/2745

1.00

-

-

Yes

778/1620

0.87

0.76-1.00

0.047

Diagnosis year

(continuous)

1410/4365

0.95

0.92-0.98

0.002

  1. CRC patients age 50-79 years diagnosed in South Australia 2003–3008
  2. Analysis with multiply imputed stage and grade, where missing, revealed similar results (i.e. identical patterns with regard to significant associations and approximately equivalent point estimates for all HRs)
  3. aTreatments received within 12 months of diagnosis